Bellicum Pharmaceuticals Inc

NASDAQ:BLCM  
1.45
-0.07 (-4.61%)
Debt Financing / Related

Bellicum Announces Positive Interim Data From Phase 1/2 Gocar-T Studies, Secures $35 Million Private Placement Equity Financing Priced At Market

Published: 12/06/2021 13:53 GMT
Bellicum Pharmaceuticals Inc (BLCM) - Bellicum Announces Positive Interim Data From Phase 1/2 Gocar-t® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market.
Bellicum Pharmaceuticals Inc - Confirmed Partial Response Observed in One Patient in First Cohort of Mcrpc Patients Treated With Bpx-601.
Bellicum Pharmaceuticals Inc - Favorable Safety Profile Observed in Initial Dose Cohort of Bpx-603 in Her2+ Solid Tumors.
Bellicum Pharmaceuticals Inc - Financing Expected to Extend Cash Runway Through Mid-2023.
Bellicum Pharmaceuticals Inc - Also Entered Into an Agreement for a $35 Million Private Placement.
Bellicum Pharmaceuticals Inc - Proceeds From Financing Will Be Used to Support Ongoing Clinical Development of Bpx-601 and Bpx-603.